Q2 2024 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript
Key Points
- Okedi, Risperidone ISM, sales increased by 141% compared to the first half of 2023, reaching EUR12.5 million.
- Gross margin improved by 280 basis points to 59.4% due to higher-margin contributions from existing CDMO customers and Okedi sales.
- ROVI's subsidiary entered into an agreement to manufacture pre-filled syringes, expected to positively impact revenue by 20% to 45% over 2023 sales starting in 2027.
- Bemiparin sales grew by 6%, with international sales increasing by 32%, driven by strong performance in China, Turkey, and Greece.
- ROVI received European approval for a new sodium heparin plant, enhancing production capacity for essential medicines.
- Operating revenue decreased by 14% to EUR329.3 million, primarily due to lower COVID-19 vaccine manufacturing revenues.
- EBITDA decreased by 28% to EUR69.9 million, with a 4.3 percentage point decline in the EBITDA margin.
- Net profit fell by 32% to EUR44.3 million in the first half of 2024.
- Sales of low molecular weight heparins decreased by 2%, mainly due to lower orders from enoxaparin partners.
- CDMO sales declined by 31% due to reduced COVID-19 vaccine manufacturing and preparation activities under the Moderna agreement.
Good morning to everybody. A warm welcome to all those attending the presentation of ROVI's first half 2024 financial results, which will start in a moment. I'm Javier Lopez-Belmonte, ROVI's Deputy Chairman and Chief Financial Officer. Joining me on today's call are Juan Belmonte, ROVI's Chairman and CEO. The presentation will be followed by a Q&A session. (Event Instructions)
Before we begin, let me remind you that the information presented in this call contains forward-looking statements based on our current beliefs and expectations. Actual results could materially differ due to the known and unknown risks, uncertainties, and other factors, and we undertake no obligation to update or revise any of these statements.
With that, I thank you again for your presence here today. And I will now hand the presentation over to Juan Lopez-Belmonte. Please, Juan, go ahead.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
